The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.

The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.

THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice.

This volume is the first of its kind to emphasize the visual approach in the diagnosis of cutaneous lymphoid infiltrates. Written and designed in an accessible yet highly detailed format by an expert in the field, this book bridges the knowledge gaps so often found when dealing with skin lymphomas. Complete with more than two hundred high quality images and illustrations, Diagnosis of Cutaneous Lymphoid Infiltrates offers pearls and pitfalls as well as differential diagnoses. Additionally, images are explained and decoded with the use of illustrations and analogies, proving to be an invaluable resource for pathologists, dermatologists, dermatopathologists, hematopathologists, and residents and fellows in these fields.

Cutaneous T-cell lymphoma (CTCL) has been described as a 'great mimicker'. The correct diagnosis hinges on effective collaboration between clinicians and pathologists to correlate pathological and clinical findings. The patient's history, lesion description and diagnostic work-up will help the pathologist interpret the histopathology, whilst the clinician’s diagnosis is aided by a clear understanding the terminology used in the pathology report. The treatment of early and advanced mycosis fungoides and its variants is potentially lifelong, with patients typically cycling among treatments, interspersed with periods of expectant therapy providing palliation and symptomatic relief. Effective management requires knowledge of the wide range of options, how they are used, and their side-effect profile, in order to tailor treatment to the individual patient. ' Fast Facts: Cutaneous T-Cell Lymphoma' is designed to help primary care providers, dermatologists, and oncologists to communicate effectively with pathologists in the diagnosis of this chronic condition, aided by over 100 superb clinical and pathological images, and to provide tailored long-term care for their patients. This concise, practical handbook will ensure clear communication with respect to the clinical presentation, histopathology, immunophenotyping and treatment of: • early and advanced mycosis fungoides and its variants • Sézary syndrome • other non-mycosis fungoides CTCLs. It is essential reading for pathologists, non-specialist clinicians and dermatology and oncology trainees.

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin including mycosis Fungoides and Sezary syndrome. This book presents the state of the art in CTCL epidemiology, clinical features, pathology, immunochemistry, diagnostic molecular techniques, staging and prognosis, and treatment. Edited by one of the leading experts in the disease, Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrome provides comprehensive coverage of the disease and presents techniques for diagnosis and state-of-the-art treatment modalities, such as ultraviolet light, steroids, and topical chemotherapeutics.